Stella Santarone

Stella Santarone

Auto-generated profile, based on publicly available information

Stella Santarone

Hematology Unit, Department of Oncology and Hematology Pescara Hospital Pescara Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
NSNicole Santoro
Nicole Santoro
ARAnnalisa Ruggeri
Annalisa Ruggeri
MLMyriam Labopin
Myriam Labopin
ABAndrea Bacigalupo
Andrea Bacigalupo
FCFabio Ciceri
Fabio Ciceri
Arnon NaglerArnon Nagler
Arnon Nagler
Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-remission treatment for adults with high-risk acute lymphoblastic leukemia (ALL). The aim of the study was to analyze results of unmanipulated haploidentical allo-SCT (haplo-SCT) for adults with ALL and to identify prognostic factors. We performed a retrospective analysis on 208 adults transplanted in EBMT centers from 2007 to 2014. Median age at haplo-SCT was 32 years and median follow-up, 31 months. Forty-four percent of the patients were in first complete remission (CR1). Stem cell source was the bone marrow (BM) for 43% and peripheral blood (PB) for 57% of patients. Myeloablative conditioning (MAC) was used for 66% and reduced intensity regimen (RIC) for 34% of patients. GVHD prophylaxis was based on post-transplant cyclophosphamide (PT-Cy) for 118 (57%) or on anti-thymocyte-globulin (ATG) for 90 (43%) plus standard prophylaxis. One hundred eighty-four (92%) patients achieved engraftment. Cumulative incidence (CI) of grade II–IV acute-graft-versus-host-disease (GVHD) was 31%, grade III–IV 11%, and chronic GVHD 29%. Non-relapse mortality (NRM) and relapse-incidence (RI) were 32 and 37%, respectively. Overall survival (OS), leukemia-free survival (LFS), and GVHD-free, relapse-free-survival (GRFS) at 3 years were 33, 31, and 26%. For patients in CR1, OS, LFS, and GRFS were 52, 47, and 40%, respectively. Disease status was the main factor associated with transplant outcomes. Use of BM was independently associated with improvement in NRM, acute GVHD, GRFS, LFS, and OS. Unmanipulated haplo-SCT may be considered a valid option for adult patients with high-risk ALL lacking HLA identical donor preferably in early disease status.

24 January 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
MRMarie Thérèse Rubio
Marie Thérèse Rubio
MDMaud D’aveni-Piney
Maud D’aveni-Piney
MLMyriam Labopin
Myriam Labopin
RHRose-Marie Hamladji
Rose-Marie Hamladji
Miguel SanzMiguel Sanz
Miguel Sanz
Arnon NaglerArnon Nagler
Arnon Nagler
The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative conditioning regimen has been poorly explored. We retrospectively analyzed 566 patients who underwent a first HLA-identical allogeneic stem cell transplantation with this conditioning regimen for acute myeloid leukemia in first complete remission between 2006 and 2013 and compared the outcomes of 145 (25.6%) patients who received ATG (ATG group) to 421 (74.4%) who did not (no-ATG group). The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate. Patients in the ATG group were older, received more frequently peripheral blood stem cell grafts from older donors, and were transplanted more recently. With a median follow-up of 19 months, patients in the ATG group had reduced 2-year cumulative incidence of chronic graft-versus-host disease (GVHD) (31 vs. 52%, p = 0.0002) and of its extensive form (8 vs. 26%, p < 0.0001) but similar relapse incidence (22 vs. 27%, p = 0.23) leading to improved GVHD and relapse-free survival (GRFS) (60 vs. 40%, p = 0.0001). In multivariate analyses, the addition of ATG was independently associated with lower chronic GVHD (HR = 0.46, p = 0.0001), improved leukemia-free survival (HR = 0.67, p = 0.027), overall survival (HR = 0.65, p = 0.027), and GRFS (HR = 0.51, p = 4 × 10−5). Recipient age above 50 years was the only other factor associated with worse survivals. These results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant outcomes due to reduced incidence of chronic GVHD without increased relapse risk.


15 August 2018 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
FSFrancesco Saraceni
Francesco Saraceni
EBEric Beohou
Eric Beohou
MLMyriam Labopin
Myriam Labopin
william arcesewilliam arcese
william arcese
FBFrancesca Bonifazi
Francesca Bonifazi
A(Acute Leukemia Working Party (Alwp) Of The European Society For Blood And Marrow Transplantation (Ebmt).
Acute Leukemia Working Party (Alwp) Of The European Society For Blood And Marrow Transplantation (Ebmt).

24 August 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SSStella Santarone
Stella Santarone
SAStefano Angelini
Stefano Angelini
ANAnnalisa Natale
Annalisa Natale
DVDoriana Vaddinelli
Doriana Vaddinelli
RSRaffaele Spadano
Raffaele Spadano
PBPaolo Di Bartolomeo
Paolo Di Bartolomeo

9 October 2017 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
SSS Santarone
S Santarone
Alessia PepeAlessia Pepe
Alessia Pepe
Antonella MeloniAntonella Meloni
Antonella Meloni
ANA Natale
A Natale
Laura PistoiaLaura Pistoia
Laura Pistoia
PBP Di Bartolomeo
P Di Bartolomeo
Hematopoietic cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers (SSCs). The aim of this retrospective study was to compare the incidence of SSC in a monocentric cohort of thalassemia major (TM) patients (n=122) who received HCT versus an hematopoietic cell donor monocentric cohort (n=122) and versus a large multicenter cohort of age- and sex-matched TM patients (n=244) who received conventional therapy. With a median follow-up of 24 years, 8 transplanted patients were diagnosed with SSC at a median of 18 years after HCT and at a median age of 33 years. Three patients died of cancer progression and 5 are living after a follow-up ranging from 10 months to 16 years after SSC diagnosis. The 30-year cumulative incidence of developing SSC was 13.24%. The occurrence of solid cancers in the hematopoietic cell donor cohort was limited to only one case for a significantly lower cumulative incidence (3.23%, P=0.02) and to 3 cases in the cohort of nontransplant patients for a significantly lower cumulative incidence (1.32%, P=0.005). This study shows that the magnitude of increased risk of SST is fourfold to sixfold for patients treated with HCT as compared with hematopoietic cell donors and nontransplant patients.